Trial Profile
A 24-month Randomized Multicenter Study Evaluating Efficacy, Safety, Tolerability and Pharmacokinetics of Sotrastaurin and Tacrolimus vs. a Tacrolimus/Mycophenolate Mofetil-based Control Regimen in de Novo Liver Transplant Recipients
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 27 Aug 2020
Price :
$35
*
At a glance
- Drugs Sotrastaurin (Primary) ; Basiliximab; Mycophenolate mofetil; Mycophenolate mofetil; Tacrolimus
- Indications Liver transplant rejection
- Focus Biomarker; Therapeutic Use
- Sponsors Novartis
- 10 Sep 2013 Results presented at the 16th Congress of the European Society for Organ Transplantation.
- 10 Sep 2013 Primary endpoint 'Treatment-failure-rate' has not been met.
- 23 Jan 2013 Status changed from active, no longer recruiting to discontinued, based on information in Novartis' Form 20-F (http://www.sec.gov/Archives/edgar/data/1114448/000104746913000377/a2212460z20-f.htm).